Azadirachtin Poisoning Treatment
Azadirachtin poisoning should be managed with aggressive supportive care focused on airway protection, seizure control, and correction of metabolic acidosis, as there is no specific antidote available.
Clinical Presentation and Immediate Management
Azadirachtin, the active compound in neem oil, causes toxic encephalopathy with vomiting, seizures, and metabolic acidosis in poisoned patients 1. The treatment approach mirrors general poisoning management principles since no specific antidote exists.
Primary Treatment Algorithm
Immediate stabilization priorities:
- Airway management: Establish airway patency and provide bag-mask ventilation if needed, progressing to endotracheal intubation for patients with decreased consciousness or inability to protect their airway 2
- Seizure control: Administer benzodiazepines as first-line anticonvulsants for seizure activity
- Metabolic correction: Aggressively treat metabolic acidosis with appropriate fluid resuscitation and sodium bicarbonate if severe
- Supportive hemodynamic management: Monitor and treat hypotension with crystalloid fluids and vasopressors if refractory
Key Clinical Considerations
The case report of neem oil poisoning demonstrates complete recovery with symptomatic treatment alone 1. This suggests that:
- Prognosis is favorable with appropriate supportive care
- No specific decontamination measures (activated charcoal, gastric lavage) are mentioned in the literature, though these may be considered if presentation is within 1-2 hours of ingestion
- Neurological monitoring is critical given the risk of toxic encephalopathy
Important Caveats
Contact poison control immediately: In the United States, call 1-800-222-1222 to reach regional poison centers staffed by board-certified toxicologists who can provide real-time guidance 2. This is particularly important for azadirachtin poisoning given the limited published experience.
Monitor for complications:
- Prolonged altered mental status requiring ICU-level care
- Recurrent seizures necessitating continuous EEG monitoring
- Persistent metabolic derangements requiring serial laboratory assessment
Avoid common pitfalls:
- Do not delay supportive care while attempting to confirm the diagnosis
- Do not assume mild initial presentation means benign course—the patient in the published case had significant toxicity requiring intensive management 1
Duration of Monitoring
Based on the single published adult case, patients should be monitored until complete resolution of neurological symptoms and metabolic abnormalities. The recovery timeline is not well-established but appears to occur within days with appropriate supportive management 1.